Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

This study has been completed.
Stanley Medical Research Institute
Information provided by (Responsible Party):
Mohini Ranganathan, Yale University Identifier:
First received: December 29, 2007
Last updated: April 1, 2014
Last verified: April 2014

This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.

Condition Intervention Phase
Schizoaffective Disorder
Drug: Cannabidiol
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Verbal short term memory [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall cognition as measured on the MATRICS Battery [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Enrollment: 36
Study Start Date: February 2009
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cannabidiol Drug: Cannabidiol
Active Cannabidiol daily over 6 weeks
Placebo Comparator: Placebo Drug: Placebo


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Schizophrenia or Schizoaffective disorder (DSM-IV SCID-confirmed),

Exclusion Criteria:

  • Women who are pregnant, nursing or unwilling to use appropriate birth control measures during study participation.
  Contacts and Locations
Please refer to this study by its identifier: NCT00588731

United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06511
Sponsors and Collaborators
Yale University
Stanley Medical Research Institute
Principal Investigator: Mohini Ranganathan Yale University
  More Information

No publications provided

Responsible Party: Mohini Ranganathan, Assistant Professor, Yale University Identifier: NCT00588731     History of Changes
Other Study ID Numbers: 0710003164, 07TGS-1082
Study First Received: December 29, 2007
Last Updated: April 1, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Psychotic Disorders
Cognition Disorders
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders processed this record on April 17, 2014